Patents Represented by Attorney Cheryl A. Liljestrand
-
Patent number: 7118743Abstract: The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is Fc?RI and HM18, and another is Fc?RI and Fc?RII. Cross-linking of these receptors with a bispecific molecule of the invention would lead to inhibition of the release of allergic mediators and amelioration of the symptoms of allergic diseases. Other diseases can be ameliorated by cross-linking ITIM/ITAM receptor pairs.Type: GrantFiled: March 16, 2001Date of Patent: October 10, 2006Assignee: Tanox, Inc.Inventors: David Thomas, Sunny Tam
-
Patent number: 7112327Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: May 27, 2005Date of Patent: September 26, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6998468Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 23, 2001Date of Patent: February 14, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 6956107Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: March 29, 2001Date of Patent: October 18, 2005Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6787524Abstract: The invention relates to a method of stimulating antibody-dependent cellular cytotoxicity to enhance the elimination of IgE-bearing B-cells comprising administering to a mammal an anti-IgE antibody, which binds to membrane bound IgE, but does not induce histamine release and administering an ISO to the mammal. The ISO may be a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence. In addition, the method may include the administration of an allergen to improve desensitization therapy.Type: GrantFiled: September 20, 2001Date of Patent: September 7, 2004Assignee: Tanox, Inc.Inventor: Nancy T. Chang
-
Patent number: 6767540Abstract: The invention relates to methods for treatment of asthma and chronic obstructive pulmonary disease (COPD) by administration of antagonists to plasminogen activator inhibitor type-1 (PAI-1). Suitable atagonists include antibodies, peptides, proteins, nucleic acids, small organic molecules and polymers.Type: GrantFiled: January 12, 2001Date of Patent: July 27, 2004Assignee: Tanox, Inc.Inventors: Chad K. Oh, Seong H. Cho, Sossiena Demissie-Sanders, David W. Thomas, Sunny Tan
-
Patent number: 6685930Abstract: Disclosed is a method of using bifunctional binding molecules, such as two linked VH-VL single chain binding molecules, to recruit a therapeutic agent to a solid tissue site. The therapeutic agent is administered separately from the binding molecules and following the administration of a remover substance which aids in clearing free binding molecules in the circulation. In the preferred mode of the invention, the binding molecules have one specificity for antigens at the target site and one for the therapeutic agent. The binding molecules are administered and allowed time to approach a maximum concentration in the extravascular space. A remover substance, preferably a liposome conjugated with antibodies which are reactive with an antigenic epitope on the binding molecules, is then administered to remove excess binding molecules from the circulation and the extravascular space.Type: GrantFiled: May 8, 1997Date of Patent: February 3, 2004Assignee: Tanox, Inc.Inventor: Tse Wen Chang
-
Patent number: 6657050Abstract: Chimeral viral-neutralizing, particularly HIV-neutralizing, immunoglobulins made up of a non-human antigen binding region and a human constant region are described.Type: GrantFiled: February 5, 1993Date of Patent: December 2, 2003Assignee: Tanox, Inc.Inventors: Cecily R. Y. Sun, Bill N. C. Sun, Michael S. C. Fung, Tse Wen Chang, Nancy T. Chang
-
Patent number: 6534058Abstract: The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.Type: GrantFiled: October 4, 2001Date of Patent: March 18, 2003Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun